1-氯-5-硝基异喹啉 | 58142-97-5

• 物质功能分类: 医药中间体 - 异喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 1-氯-5-硝基异喹啉
• 中文别名: 1-氯-5-消极异喹啉
• 英文名称: 1-chloro-5-nitroisoquinoline
• 英文别名: 1-Chlor-5-nitro-isochinolin
• CAS: 58142-97-5
• 化学式: C₉H₅ClN₂O₂
• 分子量: 208.604
• InChiKey: ABMIIJPKPFSMLK-UHFFFAOYSA-N

物化性质

• 熔点：
  183-184℃
• 沸点：
  376.8±27.0 °C(Predicted)
• 密度：
  1.484

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  存放在惰性气体中，温度控制在2-8°C。

反应信息

• 作为反应物：
  描述：

  1-氯-5-硝基异喹啉 在 盐酸 、 palladium 10% on activated carbon 、 水 、 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 33.0h， 生成 5-氨基-1(2H)-异喹啉酮
  参考文献：
  名称：

  Discovery of Benzopyridone-Based Transient Receptor Potential Vanilloid 1 Agonists and Antagonists and the Structural Elucidation of Their Activity Shift

  摘要：

  Among a series of benzopyridone-based scaffolds investigated as human transient receptor potential vanilloid 1 (TRPV1) ligands, two isomeric benzopyridone scaffolds demonstrated a consistent and distinctive functional profile in which 2-oxo-1,2-dihydroquinolin-5-yl analogues (e.g., 2) displayed high affinity and potent antagonism, whereas 1-oxo-1,2-dihydroisoquinolin-5-yl analogues (e.g., 3) showed full agonism with high potency. Our computational models provide insight into the agonist-antagonist boundary of the analogues suggesting that the Arg557 residue in the S4-S5 linker might be important for sensing the agonist binding and transmitting signals. These results provide structural insights into the TRPV1 and the protein-ligand interactions at a molecular level.

  DOI：

  10.1021/acs.jmedchem.0c00982
• 作为产物：
  描述：

  5-nitroisoquinoline N-oxide 在 三氯氧磷 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 以89%的产率得到1-氯-5-硝基异喹啉
  参考文献：
  名称：

  实用且温和的氯化杂环N-氧化物

  摘要：

  使用Vilsmeier试剂同时作为活化剂和亲核氯化物源，在C2选择性地将熔融的N-氧化的嗪N进行选择性氯化。该方法的显着特征包括操作简单，反应条件温和，底物范围宽以及仅使用化学计量的POCl3 。该方法的潜在扩展范围是一锅法氧化/氯化序列，无需分离所述的ñ氧化物中间体也被验证。

  DOI：

  10.1016/j.tetlet.2014.11.005

文献信息

• [EN] HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LA MODULATION DE NR2F6
  申请人：TES PHARMA S R L

  公开号：WO2021170658A1

  公开（公告）日：2021-09-02

  The present disclosure relates to compounds capable of modulating the activity of NR2F6. The compounds of the disclosure may be used in methods for the prevention and/or the treatment of diseases and disorders associated with modulating NR2F6 activity.

  本公开涉及能够调节NR2F6活性的化合物。本公开的化合物可用于预防及/或治疗与调节NR2F6活性相关疾病和障碍的方法。
• 5-Substituted isoquinoline derivatives
  申请人：Yamada Rintaro

  公开号：US20050020623A1

  公开（公告）日：2005-01-27

  A compound represented by the following formula (1) or a salt thereof: wherein R 1 represents hydrogen atom, a halogen atom and the like; R 2 represents hydrogen atom, a halogen atom, a C 1-6 alkyl group and the like; and R 3 represents —O—X—C(A 1 )(A 11 )—C(A 2 )(A 2l )—N(A 3l )(A 3 )(X represents propylene group etc., A 11 and A 21 represent hydrogen atom, or a C 1-6 alkyl group, A 31 represents a C 1-6 alkyl group substituted with hydroxyl group, or hydrogen atom, and A 1 , A 2 , and A 3 represent hydrogen atom, a C 1-6 alkyl group and the like) and the like, which has an inhibitory activity on the phosphorylation of myosin regulatory light chain, and is useful for treatment of diseases relating to contraction of various cells and the like.

  由以下公式（1）表示的化合物或其盐： 其中R1代表氢原子、卤素原子等；R2代表氢原子、卤素原子、C1-6烷基团等；R3代表—O—X—C(A1)(A11)—C(A2)(A21)—N(A31)(A3)（X代表丙烯基等，A11和A21代表氢原子或C1-6烷基团，A31代表被羟基取代的C1-6烷基团或氢原子，A1、A2和A3代表氢原子、C1-6烷基团等）等，该化合物对肌球蛋白调节轻链的磷酸化具有抑制作用，并且对涉及各种细胞收缩等的疾病的治疗有益。
• Design, synthesis, and biological evaluation of isoquinolin-1(2H)-one derivates as tankyrase-1/2 inhibitors
  作者：MO, JIANGWEN、PENG, YAN、WANG, YANYAN、WANG, ZHU、YAO, HAIPING

  DOI：10.1691/ph.2021.0904

  日期：——

  To investigate structure-activity relationships of tankyrase (TNKS) inhibitors, twelve new derivatives of isoquinolin-1(2 H )-one were designed and synthesized, and biological assessments were conducted. Several potent TNKS inhibitors with single- or double-digit nanomolar IC50 values were identified using enzymatic assays. Compound 11c was the most potent compound of this series and inhibited TNKS1 and TNKS2 at an IC50 of 0.009 and 0.003 μM, respectively, and showed an IC50 of 0.029 μM in a DLD-1 SuperTopFlash assay. Molecular docking results showed that compound 11c occupied a unique subpocket and formed a hydrogen bond with Glu1138 of TNKS2, which was not consistent with the patterns of known TNKS inhibitors and thus warrants further research.

  为了研究端锚酶（TNKS）抑制剂的结构-活性关系，设计并合成了十二种新的异喹啉-1(2H)-酮衍生物，并进行了生物活性评估。通过酶学检测法鉴定出几种具有单或双数纳摩尔IC50值的强效TNKS抑制剂。化合物11c是该系列中最强效的化合物，分别以0.009和0.003 μM的IC50值抑制TNKS1和TNKS2，并在DLD-1 SuperTopFlash检测中显示0.029 μM的IC50值。分子对接结果显示，化合物11c占据了一个独特的子口袋，并与TNKS2的Glu1138形成了氢键，这与已知的TNKS抑制剂模式不符，因此值得进一步研究。
• Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
  申请人：Kelly G. Michael

  公开号：US20060194801A1

  公开（公告）日：2006-08-31

  Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

  抱歉，我无法直接提供翻译结果。但我可以帮助您翻译这段文字。这段文字的中文翻译如下： 揭示了具有以下表示的公式的化合物： 这些化合物可以制备为药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，例如疼痛、炎症、创伤性损伤等。
• Substituted dihydroisoquinolinones and related compounds as potentiators
  申请人：Warner-Lambert Company

  公开号：US05177075A1

  公开（公告）日：1993-01-05

  The invention is selected, novel, and known analogs of isoquinolinones of the formula ##STR1## and pharmaceutically acceptable salts thereof; novel pharmaceutical compositions; and a method for enhancing the lethal effects for tumor cells to treatment having DNA damaging activity such as ionizing radiation or with chemotherapeutic agents.

  这项发明涉及选择的、新颖的、以及已知的异喹啉酮类化合物及其药学上可接受的盐；新颖的药物组合物；以及一种增强对肿瘤细胞的致命效应的方法，该方法包括对具有DNA损伤活性的治疗方法进行增强，例如电离辐射或化疗药物。